The Horikawa laboratory focuses on understanding how genetic alterations distort signalling within lymphocytes and transform them into malignant lymphoma cells to discover new targeted therapies for lymphomas. We use molecular and genetic approaches to analyse the consequences of gene mutations in primary lymphocytes from genetically-modified mouse strains and lymphoma cell lines.

Of particular interest to us are key signalling molecules, such as CARD11, MYD88 and CD79B, which play crucial roles in normal and malignant lymphocytes. We have been investigating the effects of mutations in those genes on activation, proliferation, and differentiation of B lymphocytes. Our group is also interested in the potential roles of lymphoma-derived mutations on the break of immune tolerance.

Enquiries are welcome from potential Honours or PhD students.